OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
DXCM DexCom
- 68.290
- +0.550+0.81%
Close Mar 31 16:00 ET
26.78BMarket Cap48.09P/E (TTM)
68.750High66.250Low5.62MVolume67.220Open67.740Pre Close381.70MTurnover1.44%Turnover Ratio48.09P/E (Static)392.11MShares141.99052wk High12.74P/B26.58BFloat Cap62.34052wk Low--Dividend TTM389.17MShs Float164.863Historical High--Div YieldTTM3.69%Amplitude0.340Historical Low67.948Avg Price1Lot Size
About DexCom Company
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
Company Profile
SymbolDXCM
Company NameDexCom
Listing DateApr 14, 2005
Issue Price12.00
Founded1999
CEOMr. Terrance H. Gregg
MarketNASDAQ
Employees10300
Fiscal Year Ends12-31
Address6340 Sequence Drive
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-200-0200
Websitehttp://www.dexcom.com
Company Executives
- Name
- Position
- Salary
- Kevin R. Sayer, C.P.A.
- President, Chief Executive Officer and Chairman of the Board
- 15.83M
- Sadie M. Stern
- Executive Vice President and Chief Human Resources Officer
- 4.91M
- Michael J. Brown
- Executive Vice President and Chief Legal Officer
- 4.96M
- Jereme M. Sylvain
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 5.85M
- Jacob S. Leach
- Executive Vice President and Chief Operating Officer
- 5.92M
- Renee D. Gala
- Independent Director
- --
- Professor Dr. Eric J. Topol, M.D.
- Independent Director
- 341.73K
- Rimma Driscoll
- Independent Director
- 343.56K
- Karen M. Dahut
- Independent Director
- 341.08K
- Bridgette P. Heller
- Independent Director
- 341.73K
- Steven R. Altman
- Independent Director
- 341.08K
- Richard A. Collins
- Independent Director
- 343.56K
- Nicholas Augustinos
- Independent Director
- 341.73K
- Mark G. Foletta
- Lead Independent Director
- 388.07K
- Kyle Malady
- Independent Director
- 341.08K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings